Pharming Group NV has received a $10 million milestone payment from its partner Santarus Inc following the successful Phase 3 trial of Ruconest, its lead drug for hereditary angioedema (HAE). The trial result was reported on 7 November. ---Subscribe to MedNous to access this article--- Company News Clinical Research